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Abstract
Viral hepatitis, secondary to infection with hepatitis A, B, C, D, and E viruses, are 
a major public health problem and an important cause of morbidity and mortality. 
Despite the huge medical advances achieved in recent years, there are still points 
of conflict concerning the pathogenesis, immune response, development of new 
and more effective vaccines, therapies, and treatment. This review focuses on the 
most important research topics that deal with issues that are currently being 
solved, those that remain to be solved, and future research directions. For 
hepatitis A virus we will address epidemiology, molecular surveillance, new 
susceptible populations as well as environmental and food detections. In the case 
of hepatitis B virus, we will discuss host factors related to disease, diagnosis, 
therapy, and vaccine improvement. On hepatitis C virus, we will focus on 
pathogenesis, immune response, direct action antivirals treatment in the context 
of solid organ transplantation, issues related to hepatocellular carcinoma 
development, direct action antivirals resistance due to selection of resistance-
associated variants, and vaccination. Regarding hepatitis D virus, we describe 
diagnostic methodology, pathogenesis, and therapy. Finally, for hepatitis E virus, 
we will address epidemiology (including new emerging species), diagnosis, 
clinical aspects, treatment, the development of a vaccine, and environmental 
surveillance.
Key Words: Viral hepatitis; Hepatitis A virus; Hepatitis B virus; Hepatitis C virus; 
Hepatitis D virus; Hepatitis E virus
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Core Tip: Viral hepatitis is a global public health concern that affects millions of people 
and causes thousands of deaths due to acute and chronic infections, cirrhosis, and liver 
cancer. Although clinical and epidemiological characteristics of hepatitis A virus, 
hepatitis B virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus infections are 
widely known, there are still other critical points that need to be discussed. This review 
focuses on the most important research topics, dealing unsolved issues and future 
research directions that can maximize practical impact in the field of viral hepatitis.
Citation: Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral 




The term viral hepatitis refers to liver inflammation related to a viral infection. As of 
today, five viruses (hepatitis A, B, C, D, and E) that selectively infect the liver, usually 
by different routes, have been recognized. In some of these viral infections, acute 
hepatitis can resolved without intervention, whereas, sometimes, the process turns 
into a chronic infection[1]. Huge medical advances made in recent decades led to the 
implementation of preventive measures, the development of vaccines and passive 
immunization strategies, and, more recently, the development of promising and 
effective treatments, at least for some forms of viral hepatitis. The results obtained by 
basic research on viruses and on viruses-cell interaction made it possible to struggle 
with what a century ago seemed an insurmountable scourge on humanity. 
Achievements in hepatitis prevention and treatment are perhaps the paradigm of 
successful translational research[1]. Nonetheless, viral hepatitis is still a global public 
health concern that affects millions of people and causes thousands of deaths due to 
acute and chronic infection, cirrhosis, and liver cancer[1,2]. This review focuses on the 
currently most important research topics and future research directions that can 
maximize practical impact in the field of viral hepatitis. Table 1 summarizes the 
principal characteristics of these hepatotropic viruses and Tables 2-6 highlight the 
main topics of viral hepatitis addressed in the present review.
HEPATITIS A VIRUS
According to the World Health Organization (WHO), 1.4 million new cases of hepatitis 
A are reported worldwide each year, with a consequent nearly 7000 deaths[3]. 
Hepatitis A virus (HAV), a member of the Picornaviridae family and the only species 
from the Hepatovirus genus that infects humans, is a non-enveloped single-stranded 
RNA virus[4]. HAV is classified into six genotypes, three infecting humans and three 
affecting simians, but there is only one known serotype[5].
Despite HAV being discovered more than 4 decades ago, it has been well charac-
terized, and its detection and diagnosis have been widely implemented; changes in the 
socio-economic conditions and the control mechanisms of the virus have triggered 
new circulation and transmission scenarios that have generated new targets for its 
assessment. Some of them are the epidemiology and molecular surveillance of the 
virus, the different vaccination schemes and immune responses, the new susceptible 
populations (after the implementation of massive vaccination), and the study of the 
virus in environmental and food matrices.
Epidemiology and transmission: Old and new challenges
Although HAV epidemiology is complex, it is changing in those countries that are 
improving their public health and sanitation policies, considering that the most usual 
routes of HAV transmission are contaminated water ingestion and the contact with 
infected individuals[6]. Three circulation patterns have historically been described for 
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Table 1 Features of different types of hepatitis virus
HAV HBV HCV HDV HEV
Family Picornaviridae Hepadnaviridae Flaviviridae Undefined1 Hepeviridae
Genus Hepatovirus Orthohepadnavirus Hepacivirus Deltavirus Orthohepevirus
Genome Positive single-
stranded linear RNA











7.5 3.2 9.6 1.7 7.2
Genotype 6 genotypes: I, II and 
III infect humans, and 
IV, V and VI infect 
non-human primates
10 genotypes (A to J) 8 (1 to 8) 8 (1 to 8) 8 (1 to 8)
Transmission Fecal-oral Parenteral, sexual, and perinatal Exposure to 
infected blood
Exposure to 
infected blood and 
body fluids
Fecal-oral; zoonotic; blood 
transfusion








Ribavirin (in chronic HEV 
infection)
Prophylaxis Yes (inactivated 
vaccine)











No Depends on the age of acquisition of the 
infection. Birth or in infancy 90%, 1 yr and 
5 yr of age 30%-50%, adulthood 5%. 
Hemodialysis patients 40%. Immune 
deficient patients 20%




Acute infection in most of 
the cases. Chronic infection 
in immunosuppressed 
populations
1It is not defined yet in any of the established viral families.
2There is only one vaccine, approved and used only in China. HAV: Hepatitis A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDV: Hepatitis D 
virus; HEV: Hepatitis E virus; DAA: Direct antiviral agents.
Table 2 Hepatitis A virus highlights
Hepatitis A virus
1 The risk of HAV infection is associated with the lack of safe water and poor and sanitation
2 Due to the vaccine introduction in childhood, young adults are becoming more susceptible to HAV infections
3 In countries where waterborne transmission is rare, outbreaks occur among men who have sex with men, injecting drug users and contaminated food
4 Since molecular detection is not routinely performed for diagnosis, surveillance programs, including viral amplification and sequencing, are needed to 
know the strains that circulate in a certain place
5 One of the greatest challenges for HAV is to increase vaccination coverage globally, still implementing the single-dose schedule, to decrease the new 
infections, and, in the long term, to achieve its eradication
HAV: Hepatitis A virus.
HAV: (1) In high endemicity areas from low- and middle-income countries, where the 
incidence varies from low to high over time and between different regions, there is a 
peak age of infection in early childhood that is frequently asymptomatic, the 
transmission pattern is person-to-person, and outbreaks are uncommon due to high 
rates of immunity from previous childhood infection; (2) In moderate endemicity 
areas, from middle-income countries (regions where sanitary conditions are variable), 
the incidence is high, the peak age of infection is in late childhood/adolescence or in 
young adults that is frequently symptomatic, the transmission pattern is also from 
person-to-person, related to food and water, and therefore outbreaks are common due 
to low rates of immunity from previous childhood infection; and (3) In low endemicity 
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Table 3 Hepatitis B virus highlights
Hepatitis B virus
1 Several host factors, such as male gender, alcohol intake, and obesity have been associated to worse disease progression. Current challenge implies 
finding genetic markers to predict the course of HBV infection. In this line, different SNPs associated with the outcome of HBV infection have been 
recently identified
2 In the last years, new diagnostic assays have been developed in the framework of the diagnosis of HBV infection. The implementation of quantitative 
HBsAg, HBcAg, and HBV-RNA in routine clinical practice could probably improve the management of patients with CHB
3 Current antiviral treatments have some shortcomings, such as poor SVR or prolonged schedules. Direct antiviral agents against different HBV targets, 
including HBV cccDNA, are under evaluation. Moreover, immunemodulatory therapies to overcome host immune impairment observed in chronic 
infections are being investigated
4 Although a safe and cost-effective vaccine is available since the 1980s, an inadequate response is achieved in particular settings. New and more potent 
adjuvants, as well as formulations that include alternative viral antigens could improve the response rate vaccination
5 The development of new antiviral therapies that enables achieving functional cure as well as accurate diagnostic methods and more effective vaccines 
will contribute with the purpose of the WHO to eliminate by 2030 hepatitis as a global health problem
HBV: Hepatitis B virus; SNP: Single nucleotide polymorphisms; HBsAg: Hepatitis B surface antigen; HBcAg: Hepatitis B core Antigen; CHB: Chronic 
hepatitis B; SVR: Sustained virological response; WHO: World Health Organization.
Table 4 Hepatitis C virus highlights
Hepatitis C virus
1 WHO global hepatitis elimination strategy aims to reduce 90% of new HCV incidence, 65% of mortality and treat at least 80% of patients
2 DAA treatment leads to regression of clinical symptoms and liver disease complications even in those patients with other comorbidities, co-infections, 
or advanced liver disease
3 The immune response plays a central role in viral elimination. The understanding of the relationship between achieving protection and activation of 
immune responses is mandatory for the development of an effective prophylactic vaccine
4 Immune response restoration after DAA treatment is also under debate, certain immune features are reinvigorated, but many immune exhaustion signs 
may persist
5 SVR after DAA rates higher than 97% are usually attained, but still, a minor group of patients (4%-5%) fails to eradicate HCV due to resistance-
associated variants, some of them arising after treatment but others naturally occurring in treatment naïve individuals
6 DAA efficacy impacts on transplantation from HCV-infected donors into infected or uninfected recipients; however, early outcome data are 
encouraging, experience is limited, and many issues remain under debate
7 HCC risk after DAA treatment has been extensively discussed; however, recent seminal reports support the notion of a reduced rate for occurrence or 
recurrence of HCC after DAA SVR
9 There are numerous HCV vaccine approaches including a few candidates who accomplished phase I trials, but a prophylactic HCV vaccine that can 
contribute to the eradication goal remains a pending issue
DAA: Direct antiviral agents; SVR: Sustained virological response; WHO: World Health Organization; HCV: Hepatitis C virus; HCC: Hepatocellular 
carcinoma.
areas from high income-countries, the incidence is low, the peak age of infection is in 
young adulthood, the transmission pattern is from person-to-person and also via food 
and water; and outbreaks are common due to low rates of immunity from previous 
childhood infection[3].
Nowadays, 34 countries have included vaccination against HAV in routine 
immunization programs among children[3]. Many countries use an inactivated HAV 
vaccine with a two-dose regimen, while other countries have successfully imple-
mented it in their immunization programs in a single-dose[3,7]. However, long term 
results of the single-dose schedule have been only partially studied. The most recent 
investigation showed sustained immunologic protection for up to 9 years, with high 
levels of antibody titers, when children were vaccinated at 12 mo[8]. More studies that 
assess long-term seroprotection against HAV after single-dose vaccination scheme are 
necessary to monitor the effectiveness of this innovative strategy. In some territories 
vaccination is also recommended for people at risk of HAV infection, like those who 
travel to regions where HAV is endemic, drug users, men who have sex with men, and 
individuals with chronic liver disease[3].
The recent improvement of socio-economic, hygienic, and sanitation measures may 
translate into an increase in the number of adults who have never been infected in 
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Table 5 Hepatitis D virus highlights
Hepatitis D virus
1 The natural course and outcome of acute hepatitis D differ according to HBV and HDV co-infection or superinfection
2 HDV and HBV genotypes in addition to host factors influence the course of chronic hepatitis
3 The implications on liver disease of HVD, HBV, and innate immunity interplay remain to be understood
4 Chronic setting leads to more severe hepatitis associated with higher rates of HCC and a faster progression to cirrhosis compared with HBV 
monoinfection. HDV pathologic changes are limited to the liver with histopathologic features that are not specific for it
5 HDV remains difficult to treat with the current available therapies, and although, several promising new therapies have been described treatment is 
still the greatest challenge in HDV infection
HDV: Hepatitis D virus; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma.
Table 6 Hepatitis E virus highlights
Hepatitis E virus
1 HEV is transmitted by the fecal-oral route (involving contaminated waters) and also as a zoonosis
2 In the last years, many studies have focused on HEV detection in environmental and food matrices, and blood products as alternative sources of 
infection
3 A new etiological agent of human hepatitis E, Orthohepevirus C, previously known to infect rats, has been recently described
4 Although most cases of HEV infection produce acute hepatitis, chronic infections seem to be an increasing problem, particularly in Europe
5 Complications and extrahepatic manifestations are also increasingly recognized
6 Only one vaccine for HEV has been licensed in China, with little known data, which limits its use
HEV: Hepatitis E virus.
childhood and therefore lack immunity. Furthermore, despite pediatric immunization 
programs, many young adults may have been above the cut-off ages to be included 
when such social programs were introduced. Therefore, young adults are now 
becoming more susceptible to HAV infections, so in areas of low and middle-
endemicity, the prevalence of symptomatic cases in this age group has increased[6]. In 
this sense, between the middle of 2016 and the beginning of 2018, several hepatitis A 
outbreaks were reported in Europe, the United States and South America, which 
disproportionately affected HAV unvaccinated young adult men, mainly men who 
have sex with men. This group presents an increased risk of infection same as persons, 
regardless sex orientation, who have oral-anal sexual contact[4]. Interestingly, through 
phylogenetic analysis accompanied by detailed questionnaires to capture the sexual 
history of the patients, it was possible to establish epidemiological links between cases, 
demonstrating that the viruses responsible for these outbreaks belonged to HAV 
genotype IA and grouped with one of these strains: VRD_521_2016, RIVM-HAV16-
090, and V16-25801[6]. This highlights the importance of carrying out a more detailed 
epidemiological record of cases, including sexual history, which will help to establish 
the source and chain of infection.
Regarding travelers to endemic regions, although the WHO has recommended their 
vaccination, it does not always happen, increasing hepatitis A cases among this group. 
Furthermore, the movements of immigrants in some areas of the world (e.g., in South 
America) led the virus to be transported from endemic areas (often without 
vaccination coverage) to non-endemic areas, introducing new viral strains[3,6]. 
Screening for immunoglobulin (Ig) G anti-HAV should be offered to this group; 
therefore, patients who test negative should be offered vaccination[4].
Detection and surveillance
Diagnosis of hepatitis A is performed by the detection of HAV IgM with serological 
assays. Specific antibodies are present in sera for at least 7 mo after infection, although 
in some individuals they remain for up to a year[4]. During acute infection, IgG anti-
HAV appears, and it remains present in serum for life[3,4]. Serological surveillance is 
assumed as the main monitoring strategy for the infection. Since molecular detection is 
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not routinely performed for diagnosis, surveillance programs, including viral 
amplification and sequencing, are needed to understand the strains that circulate in a 
certain place or that are introduced by travelers; however, it is seldom carried out. 
Molecular surveillance includes the detection and study of HAV in environmental and 
food matrices, an area of study that has been carried out in recent years. For the 
purpose of molecular surveillance, the HAV Network (HAVNET) was created in 1999
[9]. This is an international HAV network of scientists who work in reference 
laboratories of hepatitis A and share molecular and epidemiological data on this virus, 
information that is useful for the scientific community. The HAVNET aims to increase 
the knowledge of HAV infections and map the worldwide distribution of HAV strains. 
As there is a strong geographical signal in the sequences, this can be used for source 
tracking.
The study of HAV in environmental and food matrices is a valuable tool for 
monitoring circulating HAV strains, to know the sources of infection and to take 
sanitation and prevention measures. After a large outbreak of foodborne hepatitis A in 
Europe in 2013-2014, the crucial role of sequence data analysis to investigate outbreaks 
and define transmission pathways was recognized, as well as the need of the 
agreement on a common genomic region for sequencing and a common protocol to 
perform HAV detection in food[10]. In this sense, with the aim of harmonizing the 
existing protocols for HAV detection in food, the European Committee for Standard-
ization and the International Standards Organization developed and published a 
standard methodology for quantitative and qualitative determination of HAV 
(together with norovirus) in seven food matrices, using real-time (RT) polymerase 
chain reaction (PCR), which has allowed to obtain comparable results between 
laboratories[5]. Furthermore, the sequencing of a common consensus region was 
agreed to target the HAV VP1/2A junction and thus promote the protocol described in 
the HAVNET[10]. In this context, collaborations between the public health sector, the 
food sector, HAVNET, and other organizations, together with government depend-
encies, are highly recommended.
Although there is no legislation about the presence of HAV in environmental 
matrices at a global level, some countries have adopted measures for the surveillance 
of cases of food outbreaks due to HAV, which has led to strict controls of imported 
food, incorporating the mandatory control of this virus in some cases[11]. Foodborne 
HAV clinical cases and outbreaks are difficult to identify, track, and assess their 
magnitude due for many reasons: (1) The difficulty for patients to remember food 
consumption history before the onset of the disease; (2) The asymptomatic nature of 
many cases, which are not reported (in the case of outbreaks); (3) The long incubation 
period of HAV; (4) Viral contamination levels of a food item may be low and focal and, 
therefore, hard to detect; and (5) The scarce knowledge of health care teams about 
foodborne viral diseases[5].
The above issues highlight the new epidemiological scenarios of this virus, showing 
the targets to whom control and prevention actions should be directed. The main goal 
for the next years should be to increase vaccination coverage globally, implementing 
the single-dose schedule, so to decrease the new infections, and, in the long term, to 
achieve eradication.
HEPATITIS B VIRUS
The hepatitis B virus (HBV) was discovered by serendipity in the 1960s and 
subsequently several milestones were achieved such as the development of diagnostic 
tests in the early 1970s or the implementation, in the 1980s, of a safe and cost-effective 
vaccine with subsequent different therapies for the treatment of chronic hepatitis B 
(CHB) infection[12].
Despite these advances, the landscape is still far from satisfactory. Currently, an 
estimated 257 million people are living with CHB, and around 887000 deaths occur 
annually as a consequence of infection progression, mainly due to cirrhosis and 
hepatocellular carcinoma (HCC)[13]. Furthermore, it is expected in the coming 
decades that the problem of HBV infection might increase, particularly in developing 
countries, as a consequence of the limited access to diagnosis and treatment, in 
addition to the subclinical characteristics of the infection[14]. In fact, the WHO has 
proposed strategies to eliminate viral hepatitis as a Public Health problem by 2030. To 
achieve this goal, it will be necessary to implement prevention, diagnosis, and 
treatment measures, as well as to raise awareness among the population and primary 
care physicians from the infections caused by HBV[15].
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Among the current challenges to overcome are the identification of host markers 
that would allow to predict accurately the evolution of infection and the imple-
mentation of a personalized medical approach, the development of anti-HBV therapies 
that enables achieving functional cure in chronically infected patients, as well as the 
restoration of the host's immune response, the implementation of new diagnostic 
methods, and the development of more effective vaccines that would lead to 
improving prevention policies in order to reduce the global burden of HBV disease.
Host factors
HBV infection has a wide range of clinical presentations, from subclinical to 
symptomatic in the acute stage, and from inactive carrier state to active chronic 
hepatitis with different degrees of severity[16]. Epidemiological data early established 
that the course of the infection is closely related to the age at which the infection is 
acquired, being the evolution to chronicity much more frequent in individuals infected 
at birth or in childhood[17]. Additionally, male gender, heavy alcohol consumption 
(more than 60 g/d), obesity, and comorbidities, such as co-infections with human 
immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV), 
have also been reported to contribute to progression to end-stage liver disease[18-22]. 
Recently, genome-wide association studies have shown that the host genetic 
background may also affect the natural history of infection[23,24]. Several studies have 
identified single nucleotide polymorphisms (SNPs) in human leukocyte antigens 
(HLA) that have been associated with the outcome of HBV infection, either with 
clearance or progression of chronic infection, although some findings were not 
subsequently supported in other manuscripts. Among the more in depth charac-
terized, it has been found that HLA-DP (rs3077 and rs9277535) and HLA-DQ 
(rs7453920 and rs2856718) SNPs were associated to HBV persistence[25-27] Notably, 
different studies have also identified several HLA polymorphisms associated with the 
response to the HBV vaccine[28,29]. Additionally, it was also reported that cytokine, 
chemokine, toll like receptor, sodium taurocholate cotransporting polypeptide, and 
vitamin D-related genes may influence the clinical outcomes of HBV infection[24,30,
31]. Beyond the controversies observed among studies addressing the genetic 
polymorphisms involved in the outcome of HBV infection, mainly probably due to 
ethnic differences (haplotype structures and allele frequencies), these findings will 
undoubtedly help to individualize the risk of infection progression and to improve the 
effectiveness of HBV vaccination campaigns, contributing to the implementation of a 
personalized approach and a greater chance of accomplishing the achievement of 
eliminating HBV infection as a public health problem by 2030.
Diagnosis
In order to achieve global control of HBV infection, one of the main obstacles to 
overcome is the limited access to diagnostic resources. Since the 1980s, classical 
serological markers have been available, including detection of antigens s and e 
(HBsAg, HBeAg) and antibodies against antigen e and core (anti-HBe and anti-HBc), 
along with the later use of molecular markers to determine the viral load, for the 
diagnosis and management of HBV infection. The qualitative detection of HBsAg has 
been the hallmark of HBV infection. Its presence for more than 6 mo is pathognomonic 
of chronic infection, and HBsAg seroclearance is now considered the goal for 
functional cure, except for occult hepatitis B, in which HBsAg is not detected despite 
the persistence of the infection. In recent years, efforts have focused on the search for 
accurate tools for the monitoring of antiviral treatment in CHB. Complete cure of CHB 
infection implies elimination of the HBV from infected hepatocytes, which is hardly 
achievable because of the persistence of the covalently closed circular DNA (cccDNA) 
and integrated HBV-DNA. Since cccDNA detection is difficult to perform in routine 
diagnosis, surrogate markers have been developed, being the quantitative HBsAg 
(qHBsAg), the hepatitis B core-related antigen (HBcrAg), and serum HBV-RNA the 
most promising ones. In the last years, different assays to qHBsAg levels have been 
developed. In most studies carried out on HBeAg-positive patients, a positive 
correlation among HBsAg titers, serum HBV DNA, and liver cccDNA has been 
observed[32]. In contrast, this relationship was not verified in HBeAg-negative CHB 
cases[33]. The lack of correlation could be a consequence of S gene mutations 
associated with HBeAg seroconversion, affecting expression or secretion of HBsAg[34-
36]. Nonetheless, several studies have shown that qHBsAg is a useful diagnostic tool, 
together with HBV-DNA levels, to discriminate inactive carriers from HBeAg-negative 
chronic hepatitis[37,38]. Furthermore, it has been described to be useful in predicting 
sustained HBsAg clearance and liver disease progression in inactive carriers[33]. 
Likewise, baseline and on-treatment qHBsAg levels have been shown to be a reliable 
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prognostic marker of sustained virological response (SVR) in treatment with pegylated 
interferon alpha (PEG-IFN-α). Consequently, current guidelines recommend its use for 
the management of HBV therapy[39-42]. The HBcrAg, another recently developed 
marker, detects the HBcAg, HBeAg and the 22 kDa precore protein. Different studies 
indicate that HBcrAg depicts a more accurate correlation with intrahepatic cccDNA 
transcriptional activity than qHBsAg, regardless of HBeAg status[43,44]. Furthermore, 
HBcrAg has been suggested as a prognostic factor for virological remission and 
HBsAg clearance in patients undergoing antiviral treatment[45], as well as a predictive 
marker for the development of HCC[46]. Nevertheless, its clinical use remains contro-
versial. HBV-RNA detection has also raised interest as a possible surrogate marker of 
HBV transcriptional activity since serum HBV RNA levels significantly correlated with 
intrahepatic cccDNA concentrations among untreated patients[47,48]. Likewise, it has 
been suggested that HBV RNA has a predictive value as a diagnostic tool of HBeAg 
loss in patients under therapy, being proposed as a reliable marker for treatment 
discontinuation[49,50]. However, routine implementation still requires standard-
ization of the methodology. Finally, several studies have identified other promising 
markers to monitor the management of CHB patients such as quantitative anti-HBcAg 
or cccDNA determination[51-53]. Further validation for their use in clinical practice is 
still required.
Therapy
Over the last 2 decades, notable progress has been achieved in the treatment of CHB 
infection. Currently available antiviral agents include PEG-IFN-α and nucleoside/ 
nucleotide analogues (NAs) among which entecavir, tenofovir disoproxil fumarate, 
and tenofovir alafenamide are the first-line oral anti-HBV drugs due to the high 
genetic barrier to HBV resistance. Although suppression of HBV replication reduces 
the progression of liver disease and improves the outcomes in most patients, the actual 
obstacle to cure CHB is the persistence of cccDNA and integrated HBV DNA. Thus, 
the term ‘functional cure’ has been accepted as the ultimate goal to reach with HBV 
therapies[41,42]. However, PEG-IFN-α treatment has an unsatisfactory SVR rate in 
addition to several adverse effects, being therefore limited to a selected group of 
patients. On the other hand, although NAs have shown high efficacy in inhibiting viral 
replication, the HBsAg sustained clearance rate is poor, with a substantial risk of 
relapse when treatment is discontinued, the need for retreatment, and the risk of select 
drug resistant strains[54]. Therefore, the main challenge at present is the imple-
mentation of new strategies that increase the rate of loss of HBsAg or the sustained 
suppression of HBV replication compared to existing therapies by developing more 
efficient antiviral agents and immune-modulatory therapies to restore the 
functionality of the immune system. Direct antiviral agents targeting different HBV 
proteins or steps of the viral replication cycle are being evaluated. HBV entry 
inhibitors are molecules that target the NTCP receptor (NTCP: Sodium taurocholate 
cotransporting polypeptide is the host cell receptor required for HBV entry), 
preventing both the novo infection and reinfection cycles, being of great value to 
control CHB infection[55,56]. Also, HBsAg release inhibitors are promising drugs that 
combined with current antiviral treatments might help to induce HBsAg clearance
[57]. Additionally, core protein assembly modulators and small interfering RNA 
targeting HBV transcripts are under evaluation in different clinical trials[58,59]. 
Another appealing strategy implies targeting the HBV cccDNA. Several molecules and 
clustered regularly interspaced short palindromic repeats technology have shown the 
ability to inhibit synthesis or eliminate the already formed cccDNA[60]. However, they 
are still under investigation due to delivery issues and unintended off-target effects
[61]. Furthermore, antiviral agents against the protein X are also being addressed, both 
for their role in the epigenetic regulation of cccDNA and in the modulation of several 
host cell signaling pathways[62].
As mentioned above, the impairment of the host's immune system is another 
important factor for HBV persistence. Several approaches are being investigated for 
the pharmacological activation of the intrahepatic innate immune response, including 
the induction of IFN genes with antiviral properties[63] or the stimulation of toll-like 
receptors (TLR)[64], targeting adaptive cell effectors. In line with the latter strategy, 
some attractive methodologies include the use of checkpoint inhibitors that block the 
co-inhibitory receptors overexpressed in HBV-specific T cells to reverse immune 
dysfunction[65], the adoptive transfer of either genetically engineered T lymphocytes 
expressing chimeric antigen receptors or reinfusion of autologous restored T cells[66,
67], as well as therapeutic vaccination that might boost host immune response[68]. 
However, the wide range of functional deficiencies observed in patients with CHB 
represents an important pitfall for the success of these therapies. Its use together with 
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antivirals agents is expected to lead to viral elimination as well as mounting strong 
immunological surveillance that limits viral reactivation.
Vaccine
Vaccination is the most powerful tool to control the spread of HBV. Since the 1980s, a 
recombinant HBV vaccine obtained by expressing the small envelope protein 
(HBsAgS) in yeast has been available. It is currently being implemented for infants in 
more than 189 countries, and in 109 of these a dose within the first 24 h of life has been 
introduced in vaccination schedules[69]. Following the global introduction of large-
scale vaccination, a substantial decrease in the rate of HBsAg carriers was observed
[70]. After three intramuscular doses, a protective response against HBV is achieved in 
more than 90% of healthy adults and more than 95% of infants, children, and 
adolescents. However, the response rate declines with age, particularly after the age of 
40, as well as in people with obesity, smokers, comorbidities, genetic factors, or 
particular settings[71]. Failure to mount an adequate immune response is one of the 
main concerns regarding the HBV vaccine; therefore, to overcome this shortcoming, 
several attempts to enhance the immunogenicity have been addressed. On the one 
hand, new and more powerful adjuvants have been developed and evaluated, 
including liposome-based formulations, cytidine-phosphate-guanosine oligodeoxy-
nucleotide (a TLR9 agonist) or virosomes[72]. These reformulations have shown a 
considerable improvement in seroconversion rates compared to the conventional 
vaccine, particularly in individuals with poor or no response[73]. Interestingly, the 
novel adjuvants may reduce the current schedule from three to two doses, 
contributing to a higher adherence rate to compliance with the vaccination scheme, 
which is another drawback[74]. Likewise, intradermal administration has shown to 
provide better responses than the intramuscular route[75].
On the other hand, recombinant vaccines derived from mammalian cells containing 
the medium and large envelope proteins, in addition to the already used small 
envelope protein, have been developed. This approach has the advantage of antigens 
displaying the same post-translational modifications and protein folding that occurs in 
vivo. This alternative approach showed a faster seroprotection rate as compared to the 
conventional vaccine, making it of particular interest for people with poor or no 
response. Furthermore, it could protect against HBV strains carrying vaccine induced 
or spontaneous HBsAgS mutants[76]. In fact, the emergence of vaccine escape mutants 
(VEMs) and the role of the HBV genetic variability both have been considered as 
possible shortcomings of the vaccine.
Shortly after the massive implementation of the HBV vaccine, the selection of 
variants with mutations in the wild type epitope has been reported. In many countries, 
where early large-scale vaccination was introduced, along with a decrease in the 
prevalence rate of infection, over time a significant increase in the frequency of VEMs
[77] has been observed. Different studies have shown that VEMs can replicate, with 
the implicit risk of becoming the predominant strains in the coming decades. In 
addition to the selection pressure exerted by the implementation of large scale 
vaccination, due to the overlapping of the open reading frames in the HBV genome, 
mutations in the Pol gene can affect the S gene[78]. Consequently, the use of antiviral 
agents targeting the viral polymerase indirectly promotes the selection of mutants 
affecting the HBsAgS recognition by vaccine-induced antibodies. Beyond these 
assumptions, the transmission of VEM is a very unusual event and, although its strict 
vigilance is recommended, it does not pose a threat to the control of HBV infection. 
Therefore, the introduction of mutated antigens in the vaccine formulation is not 
currently being considered[79].
Finally, the genetic variability of HBV may represent a more significant problem 
than VEMs. Based on the genetic diversity, HBV is classified into 10 genotypes (A to J) 
and several subgenotypes. The HBV vaccine used today was developed decades ago, 
when the existence of the different HBV genotypes was unknown, using HBsAgS of 
genotype A2 as a prototype. Case reports of vaccinated people subsequently infected, 
mainly with the most divergent genotypes, have been described[80-82]. Although 
there is a paucity of data regarding cross-genotype preventive effect, greater 
protection against homologous genotype/sub-type than against heterologous strains 
of HBV have been reported[83]. However, empirical data from regions where the most 
divergent genotypes are prevalent suggests that cross protection is sufficient to 
prevent infection. Therefore, HBV diversity would not represent a major obstacle to 
the prophylaxis of infection.
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HCV
In 2020 the Nobel Prize in Physiology or Medicine was awarded to the Americans 
Harvey J Alter (United States National Institutes of Health) and Charles M Rice 
(Rockefeller University) and to the British Michael Houghton (University of Alberta) 
for the discovery of the HCV. Alter demonstrated the existence of a non-A non-B 
hepatitis virus-associated with post-transfusion hepatitis in 1975, Houghton cloned 
and identified the viral genome and renamed it as HCV in 1989, and Rice established, 
from an edited version of the virus genome, a robust in vitro replication system in cell 
cultures in the 1990s and thus laid the foundation for future genetic and functional 
analysis[84-86].
Epidemiology and treatment
HCV is an enveloped single-stranded RNA virus of the Flaviviridae family. Due to a 
lack of proofreading activity of HCV RNA-dependent RNA polymerase (NS5B) and 
their high replication rate, a large number of viral variants are produced during 
infection[87]. Eight genotypes have been described, among them genotype 1 is 
prevalent worldwide, while the others were each characterized in different geographic 
regions, that is genotype 2 in West Africa, genotype 3 mostly in South Asia, genotype 4 
in Central and North Africa, genotype 5 in South Africa, genotype 6 in South-East 
Asia, and genotype 7, which has been isolated from central African immigrants in 
Canada[88,89]. Recently, the novel genotype 8 was described as endemic in India[90].
HCV is estimated to infect more than 1% of the global population, and around 80% 
develop a slowly evolving, asymptomatic chronic liver disease characterized by cell 
damage, inflammation, and fibrosis that can progress, after a few decades, to cirrhosis 
in 30%-40% of cases or to HCC in 1%-3% of them[91]. Thus, HCV infection is strongly 
related to liver transplantation. In the absence of a vaccine, HCV treatments went 
through different stages, starting with prolonged regimens based on interferon as an 
immune system modulator with cure rates of less than 50% and high adverse effects, 
and going through successive generations of direct-action antivirals (DAA). However, 
the real improvement of the DAA regimen began in 2013, when an interferon-free 
treatment was available; since then, several DAA schemes targeted against the 
protease, the NS5A protein, or the polymerase became the standard of care. Currently, 
treatments are oral with almost no side effects and with SVR rates higher than 97% 
after 8 to 12 wk. Nowadays, successful treatment leads to regression of clinical 
symptoms and complications of liver disease even in those patients with other 
comorbidities, co-infections, or advanced liver disease[92-94]. In this new scenario, as 
mentioned above, in 2016 the World Health Assembly approved a global strategy to 
achieve viral hepatitis elimination (C and B), which concerning HCV aims to reduce 
90% of new HCV infections (incidence), 65% of deaths (mortality), and treat at least 
80% of patients who require treatment[95,96]. However, this objective is far from being 
reached. On the one hand, it is critical that each country implements systematic and 
organized programs of silent carrier detection to overcome the suboptimal rates of 
HCV screening. On the other hand, it is necessary to ensure access to treatment for all 
infected people, which is still difficult due to the high cost of it. Finally, it is essential to 
carry out primary prevention tasks to avoid the generation of new cases and the 
reinfection of patients already cured, especially in the groups at greatest risk[95,96].
Pathogenesis and immune response
Chronic hepatitis C pathogenic mechanisms as well as the immune response 
participation in the generation of liver damage are still topics of interest[91,97]. It has 
been thoroughly described that HCV alters liver homeostasis, leading to stress and 
inflammation[98]. The liver microenvironment is extremely complex with numerous 
immune cell populations that, along with the cytokines that they produce, play a 
central role in the viral elimination; thus the interplay between virus and host immune 
response may influence infection outcome[99-101]. Remarkably, in the chronic stage, 
the role of the immune cells becomes more complex since their altered functionality 
would contribute to liver damage[102]. Cellular immune surveillance of HCV infection 
induces interferon production and activates innate immune response, hence 
controlling the infection. As part of the innate immune response, natural killer, 
dendritic, and Kupffer cells present viral antigens from infected hepatocytes to the T 
and B lymphocytes, which in turn contribute to virus control. The immune system 
triggering is not enough to control HCV infection and in consequence, a persistent 
infection is established. However, the results behind this data are controversial, and 
the underlying mechanism by which various cell populations are involved is still 
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under discussion.
The understanding of the relationship between achieving protection and the 
activation of both innate and adaptive immune responses is mandatory for the 
development of an effective prophylactic vaccine that may control infection and 
transmission. Moreover, the restoration of the immune response after DAA treatment 
is also under debate, particularly because most reports have focused on immune cells 
in peripheral blood, and little is known related to the intrahepatic immune 
environment after rapid clearance of chronic HCV. Remarkably, a double scenario 
arises after DAA treatment, certain immune features are reinvigorated but many 
immune exhaustion signs may continue after viral elimination[103]. The majority of 
pro-inflammatory cytokines and chemokines reached normal values after long-term 
monitoring albeit IFN-α and tumor necrosis factor-related apoptosis-inducing ligand 
maintained high levels for months after treatment[104,105]. Regarding HCV-specific T 
cells, a partial recovery of the functionality, mainly proliferation capacity, was 
described. Nevertheless, it does not apply for every patient, and the restoration level 
was not homogeneous for all individuals. The suppression of HCV replication led to a 
decrease in expression of T lymphocyte exhaustion markers and an increase in HCV-
specific IFN-γ responses after treatment[94,106,107]. However, the restoration of 
exhausted HCV-specific CD8+ T lymphocyte surface phenotype does not result, per se, 
in a complete functional restoration. Regarding CD4+ T cells, HCV antiviral treatment 
leads to a shift from a T helper 1 cell to a follicular helper T cell (Tfh) environment 
within HCV-specific cells. Likewise, HCV-specific CD8+ T lymphocytes, Tfh cells are 
likely to persist in an antigen-independent manner[108]. Furthermore, in chronic 
hepatitis C, regulatory T cells are usually elevated and display an activated phenotype 
in the course of infection that persists even after DAA therapy[109]. Natural killer 
(NK) cells have an important role in HCV infection control; however, phenotype and 
function of NK cells are altered in chronic HCV patients[110]. In recent years, several 
groups have investigated the recovery of the altered NK cell compartment upon 
successful antiviral treatment, but it is still a matter of research whether an active 
reinvigoration via certain signaling pathways or the resolution of inflammation after 
virus elimination are responsible for a seemingly restored NK cell compartment. 
Hence, such a persistent challenge of the immune system might trigger irreversible 
damage that in turn could affect the success of any therapeutic vaccine design or even 
any immunotherapy approach against HCC[94,103,111].
DAA resistance-associated variants 
Current DAA therapy has demonstrated high efficacy, but still in a minor group of 
patients (4%-5%) it does not succeed in eradicating HCV, largely due to inadequate 
adherence but also due to relapse or viral fitness[112]. Since HCV is a rapidly evolving 
RNA virus, the exposure to DAAs triggers strong drug selection favoring mutants that 
offer partial resistance to them. Thus, the high SVR achieved with DAA still faces the 
challenge of resistance-associated variants (RAVs), some arising after treatment but 
others naturally occurring in treatment naïve individuals[113,114]. DAA treatment 
failure may be attributable to advanced liver disease, suboptimal therapy adherence, 
and the presence or generation of NS5A mutations[112]. The three HCV non-structural 
proteins have different RAV prevalence, which may be related to their distinct roles in 
the HCV life cycle that defines the resistance genetic barriers[115]. RAVs affecting each 
of the DAA classes have different properties and occur most commonly in the NS5A 
region, less commonly in the NS3 region, and uncommonly in the NS5B region. In all 
first-line DAA regimens, NS5A inhibitors are a crucial component because their RAVs 
have direct clinical impact[114,116]. Treatment-emergent RAVs that remain at high 
frequency after the end of therapy often have other fitness compensating mutations 
and may be more difficult to treat. Nowadays, there are several options for patients 
who have failed to respond to first line DAA therapy, and more than 90% of these 
patients are able to achieve SVR following retreatment, but the selection of the 
appropriate therapy depends on several factors and may require genotype and 
resistance testing. It should be noted that there are some notable genotype-specific 
differences with respect to retreatment, particularly in the case of prior exposure to 
NS5A inhibitors in patients with genotype 1 infection. Rescue treatment options with 
multiple targeted therapies, such as the pangenotypic combinations, sofosbuvir/ 
velpatasvir/voxilaprevir (Vosevi), and glecaprevir/pibrentasvir (Mavyret), were 
effective in the majority of cases with DAA failure[112]. Interestingly, a recent 
European multicentric study showed that even Vosevi can fail in genotype 3 and 
genotype 1a infected individuals with cirrhosis, but this failure is not associated with a 
specific pattern of RAV. It is important to note that rescue treatment with multiple 
targeted therapies was effective in the majority of patients[117].
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DAA treatment in the context of solid organ transplantation
The field of solid organ transplantation (SOT) has also been benefited with DAA 
development[118,119]. The efficacy of DAA has created a new opportunity to improve 
survival in end-organ failure patients through greater access to organ transplantation, 
since transplanting organs from HCV-infected donors into infected or uninfected 
recipients is now under consideration. Altogether, this has led to a better transplant 
outcome due to healthier patients receiving SOT and a significant reduction of waitlist 
mortality and healthcare costs. In the post-liver transplantation setting, early treatment 
is now recommended due to the high efficacy of DAAs, in association with a low side 
effect profile and easily mitigated drug-drug interactions[118,119]. The optimal 
treatment duration for each organ is not yet clear; in the years to come there will be 
increasing data and hopefully standardization of treatment. Some reports proposed 8-
12 wk of DAA treatment for liver transplantation, but 2-4 wk seems to be enough for 
other organs[118,119]. However, it should be kept in mind that although it is expected 
that treatment eliminates the risk of infection, this is not a certainty; since the 
persistence of HCV RNA in peripheral blood mononuclear cells and/or the liver has 
been shown to occur post-SVR in liver transplantation recipients, with unclear clinical 
consequences. Although early outcome data are encouraging, the overall experience is 
limited, and many ethical issues and scientific questions remain, such as avoidance of 
selection bias, the optimal timing of DAA therapy, detailed evaluation of drug-drug 
interactions between DAAs and immunosuppressants, and long-term graft-patient 
outcomes. Moreover, there is no data on possible long-term hepatic and extrahepatic 
adverse effects associated to HCV exposure, even among those cured of the infection. 
As such, transplanting livers from HCV-infected donors into uninfected recipients 
requires special approval from governing bodies in the United States and in nearly all 
countries around the world[120].
HCC as a consequence of DAA treatment
Regarding the plausibility of HCC development in the context of DAA therapy, a risk 
reduction would be expected as viral clearance reduces morbidity and mortality rates. 
It should be considered, however, that HCV has a direct carcinogenic potential since 
some of the HCV-encoded proteins interact with cellular regulatory factors and 
produce oxidative stress, DNA damage, and deregulation of host cell checkpoints, 
thus promoting tumorigenesis[121,122]. Because HCV is an RNA virus and its genome 
does not undergo reverse transcription into DNA, its carcinogenic effects cannot be 
attributed to its integration into the hepatocyte genome. Lately, the risk of occurrence 
or recurrence of HCC in HCV patients who received DAA has been debated. IFN-
based therapy reports demonstrated that achieving a SVR significantly diminished the 
risk for HCC[123]. Furthermore, these patients recover liver functionality with a 
positive impact on long-term disease-free survival[121,124]. On the other hand, initial 
reports on DAA therapy exposed a potential high risk of HCC occurrence and 
recurrence after treatment[121,125-127] and hypothesized that the occurrence of HCC 
would be the result of the emergence and spread of a pre-treatment "orphan" tumor 
clone that escapes immunological surveillance. The rapid virus elimination following 
DAA therapy may lead to an imbalance of the immunity that may rebound on 
immune control of the neoplastic clone[121]. However, the initial results were not 
conclusive or were even opposed due to the lack of homogeneity in the study design
[125]. Recent seminal reports support the notion of a reduced rate for occurrence or 
recurrence of HCC after SVR obtained after DAA treatment, so the impact of DAAs on 
HCC risk is nowadays an old tale[93,128,129]. However, the time of DAA therapy 
initiation in HCC HCV positive patients is still controversial since it seems to condition 
treatment success[2,125,130,131]. In this sense, the best advice for physicians is to 
follow approved international or local guidelines and to keep updated to minimize 
risks or therapeutic failures[2,125,130,131].
Vaccine
The development of a prophylactic HCV vaccine that can contribute to the eradication 
goal still remains as a pending issue. The diversity of the virus, different behaviors of 
the virus in animal models or cell cultures, the limited models or individuals to test the 
vaccines, and the insufficient understanding of protective immunity against HCV are 
barriers to the development of an effective vaccine. It has been described, both in 
chimpanzees and humans, that immune system surveillance of primary infection is not 
necessarily efficient in controlling a recurrent one[132,133]. Therefore, spontaneous 
HCV immune control does not certainly generate protective immunity, hence 
diminishing confidence that prophylactic vaccination is possible. Furthermore, 
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compared to the initial HCV infection, a lower peak and duration of viremia charac-
terized the reinfection in the same individual[113,134,135]. A faster and more effective 
viral replication control at second exposures indicates an adaptive immune response 
that may avoid chronic infection even though it cannot prevent reinfection. Therefore, 
a vaccine that induces T and B cell responses against multiple HCV genotypes and 
impedes the selection of virus escape mutants is needed[111,113]. While attenuated 
vaccines by the passage of the virus in non-human primate cell lines could be 
produced and suppress or inactivate genetic virulence factors, HCV does not replicate 
at high levels in non-human primate cell lines and no virulence factors have been 
defined for HCV yet. Therefore, concerns related to the production and the potential 
risk of attenuated vaccines could limit their utility[113]. In addition, HCV culture 
strains have adaptive mutations that enhance their ability of in vitro replication with an 
unknown impact on replication in humans. Inactivated whole HCV vaccines were also 
described; however, the lack of effective processes in the later phases for the 
purification of HCV represents an obstacle for the development of a complete virus 
vaccine[136]. On the other hand, there are numerous approaches involving viral 
antigens as immunogens, namely DNA-vaccines, adenovirus-based strategies, virus-
like particles, HCV recombinant antigens conjugates to HBsAg, and HCV peptides in 
different delivery platforms[113,137-143]. Most of these candidate’s vaccines have 
triggered humoral and cellular immune responses in rodents, and a small subset of 
them causes immunity in macaques, and fewer candidates in chimpanzees[113,144-
148]. Likewise, only a few HCV vaccine developments accomplished the goal of phase 
I trials in volunteers not at risk for HCV infection[113,149-153]. Given that the partial 
results of the clinical trials are not completely encouraging, new strategies are required 
to improve and/or maintain antiviral immunity, and therefore there is a long way to 
go until a successful HCV vaccine could be used[137].
HCV infection is an example of the success of translational research, as a result, 
HCV infection is the only chronic viral infection that can be cured, and the hepatic or 
extrahepatic manifestations are mostly reversible[154]. Many countries are making 
significant progress in their fight against it, but HCV surveillance is at the base of any 
effort to control and eliminate the disease, since early diagnosis can prevent health 
problems that may result from infection and prevent transmission of the virus. The 
road is long, but with clear objectives the goal can be achieved.
HDV
In 1977, Rizzetto et al[155] identified a new antigen in the liver and serum of HBV 
infected patients who showed more severe hepatitis than their counterparts[155]. This 
observation led to the discovery of the HDV (also called a satellite virus), an unusual 
defective virus whose genome consists of a negative single-stranded circular RNA that 
encodes a single nucleocapsid protein, the delta antigen. The HDV virion, of 36 nm, 
consists of a ribonucleoprotein core complex and a lipoprotein envelope composed of 
the three HBV envelope proteins: Small (S-), medium (M-), and large (L-) HBsAg. HBV 
presence is mandatory for HDV replication, since HBsAg is required for HDV cell 
entry by NTCP, virion assembly, and export; however, its RNA replication is 
autonomous. HDV is maintained as episomes in the nucleus of the infected 
hepatocytes and transcribes the viral RNAs on behalf of the host cell machinery[156].
Clinical, epidemiological, and virological features
Two different scenarios may allow HDV infection: Either HBV and HDV simultan-
eously infect the host (co-infection) or HDV infection occurs in CHB patients (superin-
fection). In general, HDV is a highly pathogenic virus associated with more severe 
forms of acute hepatitis, including fulminant hepatitis. The natural course and 
outcome of acute hepatitis D differ according to the way infection takes place, whereas 
only 2% of coinfections evolve to chronicity, superinfection results in chronic infection 
in over 90% of the cases[157]. Irrespective of the type of infection, the chronic state 
leads to more severe hepatitis associated with higher rates of HCC and a faster 
progression to cirrhosis compared with HBV monoinfection, increasing this risk three 
times among HDV-HBV coinfected patients[157,158]. At least 5% of individuals with 
chronic HBV are co-infected with HDV, raising the HDV global burden of infection to 
an estimate of more than 62 million people, nearly 1% of the world’s population[2,
159]. Despite having a global distribution, HDV has a higher prevalence in Africa 
(Central and West Africa), Asia (Central and Northern Asia), Pacific Islands, Middle 
East, Eastern Europe, South America (Amazonian basin), and Greenland[2,160,161].
In addition to host factors, HDV and HBV genotypes influence the course of chronic 
hepatitis[162]. HDV genome analysis disclosed at least eight distinct HDV genotypes 
(HDV-1 to -8), with some displaying two to four sub-genotypes. Infection with 
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genotype 1, the most common one, has been associated with a wide spectrum of 
disease severity, while other genotypes appear to be more geographically restricted 
and to be linked with different degrees of disease severity. Infections with either 
genotype 2 and 4, the most commonly genotypes found in the Far East, generally 
develop milder forms of liver disease, whereas genotype 3 exclusively found in the 
Amazon region, has been documented as one of the most aggressive types, associated 
with severe and fulminant hepatitis outbreaks. HDV-5 is predominant in West Africa, 
whereas HDV 6, 7, and 8 were isolated in patients from central Africa[157]. 
Furthermore, HBV genotype could influence HDV infection and replication, being 
HDV viral loads are lower in patients co-infected with HBV genotype A, whereas co-
infection is more frequently seen in genotype F CHB patients[156].
Transmission and diagnosis
HDV and HBV routes of transmission are alike, namely intravenous drug users or 
exposure to infected blood products and serous body fluids, but HDV mother to infant 
transmission is rare[162]. HIV infection, intravenous drug users, men who have sex 
with men, and individuals from areas of high HDV prevalence who are HBV-infected 
are at risk for co-infection with HDV[2,161]. The HDV antigen is only detectable 
transiently, therefore the diagnosis is made by measuring anti-HDV antibodies. HDV 
IgM appears in blood between the first and third weeks after infection and remains 
positive in the chronic phase with variable levels according to disease activity. HDV 
IgG is also detectable during active and resolved infection, so this test is useful for the 
screening of chronic or past HDV infection, while HDV RNA detection is applied to 
confirm active chronic hepatitis and to supervise therapy response. Anti-HDV IgM 
and HDV RNA assessment, together with HBV infection acute markers, should be 
tested to distinguish between acute co-infection HBV/HDV vs HDV superinfection
[163].
Immune response and pathogenesis
Experimental and clinical studies suggested that HBV is a weak inducer of innate 
response and has developed strategies to evade innate immune sensing, whereas HDV 
has shown to activate the IFN pathway via melanoma differentiation antigen 5. It has 
been suggested that both HBV and HDV could inhibit the janus kinase/signal 
transducer and activator of transcription signaling pathway and hence the response to 
exogenous IFN. So, the constant activation of the IFN pathway may contribute to 
chronic viral pathogenesis; however, the implications on liver disease of HDV and 
HBV and innate immunity interplay remain to be understood. HDV activation of the 
type-I IFN pathway may promote an increase in the NK cell number, thereby inducing 
the killing of HBV-specific CD8 T cells by tumor necrosis factor-related apoptosis-
inducing ligand-dependent mechanisms, hence worsening HBV pathogenesis in co-
infected patients. Additionally, it has been described that HDV proteins affect 
autophagy by promoting HDV replication, cause oxidative stress, and modulate the 
transforming growth factor-β and nuclear transcription factor-kappa B signaling 
pathways. However, most of the studies have been performed in artificial systems that 
naturally tend to overexpression, so most of them need to be confirmed in actual 
infectious systems[156,164,165].
HDV pathologic changes are limited to the liver with histopathologic features that 
are not specific for it, but they tend to be more severe in HDV disease. The hepatocyte 
injury is typically focal, except in the most severe cases when confluent necrosis 
occurs, leading to submassive or massive necrosis accompanied by infiltration of 
inflammatory cells within the collapsed lobules and in the portal areas[157]. Liver 
biopsy is still of election to achieve an accurate inflammation grading and fibrosis 
staging since fibrosis noninvasive markers are not reliable in chronic HDV infection. 
The higher inflammation in HDV compared to HBV monoinfection alters elastography 
measurement, so the accuracy of transient elastography seems to be reasonable to 
detect cirrhosis but remains to be validated for grading lesser degrees of fibrosis[1,166-
168].
Viral tropism
Several studies have proved the ability of HDV to replicate in a variety of tissues and 
cells after transfection; moreover, HDV-like viruses have been isolated from other 
species (birds, snakes). These findings question the hypothesis of an escaped human 
gene HDV origin and also alludes to the cooperation with other viruses to egress. 
Furthermore, it has been shown that HDV ribonucleoprotein can be assembled with 
envelope proteins that come from non-HBV related viruses, raising the question of 
HDV may also be harbored by other viruses[156].
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Treatment
The ability to achieve SVR in the treatment of HDV remains uncertain given the high 
rates of late relapse. Therefore, HDV remains difficult to treat with the current 
available therapies. PEG-IFN is the election therapy but the absence of HDV treatment 
guidelines generate uncertainty concerning protocols. Nucleoside/NAs are ineffective 
because they do not reduce HBsAg levels, which is required for HDV propagation. 
However, despite the presence of HDV typically suppressing HBV replication, 
nucleoside/NA (entecavir or tenofovir) is generally recommended, particularly in 
patients with cirrhosis, regardless of HBV replication status[1]. Nevertheless, the Hep-
Net International Delta Hepatitis Intervention Trial, a large multicenter program, 
treated patients with PEG-IFN-a-2a and/or adefovir for 48 wk. Six months after 
treatment completion, 28% of patients who were treated only with interferon 
continued to have undetectable HDV RNA with no additional benefit compared to 
those who also received adefovir and showed no response in individuals treated with 
adefovir alone. In a consecutive study in which patients were treated with PEG-IFN-α 
with or without tenofovir, only 23% of patients with interferon therapy presented 
levels of RNA under the detection limit 24 wk after stopping treatment with no extra 
benefit from the additional use of tenofovir[169]. Therefore, treatment is still the 
greatest challenge in HDV infection. So far, several promising new therapies have been 
described, some of which in combination with interferon, may result in sustained 
clearance of HDV. In this regard, myrcludex and lonafarnib are two promising 
treatments that are at the most advanced development stages. Myrcludex is an entry 
inhibitor while lonafarnib prevents HDV secretion, preventing both de novo and 
reinfection cycles. Other therapies are under evaluation in different clinical trials, such 
as hepcludex which has already been partially approved owing to its safe profile[170,
171].
Despite these promising advances, we are in need of treatments achieving 
permanent HDV RNA suppression since high rates of relapse are associated with 
current IFN therapies in addition to increased transaminase levels after discon-
tinuation. Interestingly, HDV coinfection prior to liver transplantation reduces the risk 
of graft reinfection and is associated with better patient survival than HBV-monoin-
fected patients. However, reinfection with HDV following liver transplantation may 
still occur, but tends to be aborted if HBV recurrence is also prevented[2,172].
The current knowledge on HDV highlights that the critical points to be addressed in 
future research must be directed to explain the virus and the immune system 
interaction linked to the pathogenesis that might allow treatment improvement against 
chronic liver disease produced by HDV.
HEPATITIS E VIRUS
The hepatitis E virus (HEV) is a causative agent of endemic and epidemic hepatitis 
worldwide, producing approximately 20 million infections every year, leading to an 
estimated 3.3 million symptomatic cases[173]. It is a spherical, non-enveloped virus 
that belongs to the family Hepeviridae, genus Orthohepevirus, a genus that is divided 
into four species (A-D)[174]. The strains of species A (Orthohepevirus A) are 
responsible for hepatitis E in humans. It comprises eight genotypes (HEV-1 to 8) 
displaying a geographical distribution and different epidemiological patterns. 
Genotypes that infect humans are 1-4 and 7[174,175].
HEV represents a significant public health challenge in resource-limited settings, 
mainly from Asia and Africa. In industrialized countries, it has historically been 
incorrectly regarded as having little clinical relevance[4]. However, in the last years, it 
has been recognized as an emerging and often undiagnosed disease in developed 
countries and some places of America, based on increasing reports of non-travel 
associated sporadic cases and chronic clinical presentations[176].
Epidemiology and transmission: Old and new challenges 
Two epidemiological patterns have been observed for HEV. The first one is related to 
genotypes 1 (HEV-1) and 2 (HEV-2), which infect only humans and are transmitted 
mainly by the fecal-oral route, through water contaminated with the virus, resulting in 
frequent sporadic cases and occasional large outbreaks. These genotypes circulate in 
areas of high endemicity, generally in developing countries (due to poor sanitation) in 
Asia, the Middle East, North Africa, and some parts of America[175-177]. The second 
pattern, observed mainly in industrialized countries and some parts of America, is 
related to the zoonotic transmission of HEV genotypes 3 (HEV-3) and 4 (HEV-4), in 
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which pigs are considered a viral reservoir, although these viruses have also been 
detected in other animals, such as wild boar or deer[175,177]. Humans can become 
infected through direct contact (with many studies showing that farmers have higher 
levels of HEV antibodies)[178] or by ingestion of raw-undercooked animal meat or 
derived products, such as sausages or pates, that contain the virus[5]. Shellfish, fruits, 
and vegetables have also been implicated in viral transmission, probably due to pig 
slurry contaminating watercourses, which are used for irrigation, or being used as 
fertilizer[4,5]. HEV-3 has a worldwide distribution, while HEV-4 is restricted to Asia 
and Europe[177]. Interestingly, genotype 7 (HEV-7) has only been described in the 
Middle East and Dubai, from sporadic human cases and camels[174].
Since HEV is transmitted by the fecal-oral route (involving contaminated waters) 
and also as a zoonosis (having animal reservoirs), many studies in the last years have 
focused on HEV detection in environmental and food matrices as sources of HEV 
infection[177]. HEV has been detected in many environmental matrices, such as 
sewage, recreational waters (river, creek, dam), and tap waters, showing fecal contam-
ination of the environment[179,180]. Viral presence in sewage represents an indicator 
of viral excretion of a given population, so it is useful for monitoring HEV circulation
[181]. Water resources that are contaminated with wastewater are the main origin for 
the dissemination of enteric viruses and, in consequence, they could represent a viral 
reservoir with a dramatic impact on the population's health[179].
HEV food contamination that is not derived from pork is another route that is 
currently being studied, such as shellfish, fruits, vegetables, or milk, which have been 
postulated to be possible sources of infections, particularly in places where sporadic 
cases without an epidemiological link occur[5]. Many new lines of study are focused 
on the research of HEV in foods, methodologies for its detection in food matrices, and 
food outbreaks. The knowledge of these sources of infection will allow for 
improvements in the prevention of HEV infection.
Additionally, vertical transmission from mother to child[182] and transmission 
through blood transfusion[183] have also been described, but as less frequent routes. 
However, the transfusion route is currently becoming more relevant since an 
increasing number of cases are being reported in Europe and Asia[176]. This is partic-
ularly important for immunosuppressed populations since these patients could 
develop chronic infections and are commonly subjected to blood transfusions. 
Asymptomatic carriers of HEV could play a possible role as human viral reservoirs, 
and the virus can be transmitted during the donation, when the volunteer donates 
blood prior to the onset of the acute stage of hepatitis E[176]. In response to the threat 
posed by HEV to transfusion safety, many European countries have implemented 
screening for HEV-RNA in blood products, and many others are considering to do so
[183]. However, in the rest of the world, there is still a lack of knowledge about this 
route of transmission.
In recent years, a few cases of acute and chronic human hepatitis E attributed, for 
the first time, to the HEV-C (Orthohepevirus C) species were reported in many parts of 
the world. Until now, this virus had only been detected in rats and ferrets (known as 
rat-HEV), and belongs to the genus Orthohepevirus, as well as the human-infecting 
HEV-A, although they are very divergent[4,184]. HEV-C genotype 1 was identified in 
both immunocompetent and immunocompromised patients who displayed acute and 
chronic infection as described in a recent large prospective study in Hong Kong, 
positioning this virus as a new etiological agent of hepatitis E. It is important to 
mention, as observed in one case, that the pre-existing HEV antibodies did not protect 
against HEV-C genotype 1. Also, routine hepatitis E diagnostic tests may overlook 
HEV-C infection[184]. Therefore, this is a new challenge in the field of viral hepatitis 
and specifically in understanding HEV epidemiology.
Clinical features
In most cases the infection produces an acute self-limited illness with a variety of 
clinical manifestations, ranging from asymptomatic course to acute liver failure, 
resulting in fatality rates of 0.2%-4%. The most common symptoms are abdominal 
pain, nausea, vomiting, anorexia, fever, and jaundice[182]. The course of the disease 
could be more severe in pregnant women infected with HEV-1, with high maternal, 
fetal, and neonatal morbidity and mortality rates, as high as 25%[182]. In turn, it has 
been described in individuals who have chronic liver disease that the mortality rate 
increases when infected by HEV[174]. Chronic HEV infections have been identified 
among immunocompromised persons infected with HEV-3 or HEV-4, including 
patients receiving cancer chemotherapy, recipients of organ transplant, and HIV-
infected persons. In these cases, HEV-RNA had been detected in serum and/or stool 
samples for at least 6 mo[175,177]. Chronic hepatitis E seems to be an increasing 
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problem, particularly in Europe, where areas with high chronicity rates have been 
identified.
Hepatitis E also shows a spectrum of serious complications and extrahepatic 
manifestations, which are being increasingly recognized[174]. Some of them include 
acute or chronic liver failure, neurological disorders, pancreatitis, renal injury, 
cryoglobulinemia, hematological disorders, and thyroiditis[174,175,177]. The mecha-
nisms of HEV-associated extrahepatic injuries are not fully understood yet and 
represent a challenge for the study of hepatitis E and its management.
Diagnosis
Diagnosis of hepatitis E infection can be carried out using direct techniques, which 
allow for the detection of the viral antigens and nucleic acid, as well as by the 
detection of IgG and IgM HEV-specific antibodies, although it may require a 
combination of both, molecular and serological assays, to confirm infection and for 
monitoring the treatment in chronically infected patients[185]. Laboratory diagnostic 
techniques for HEV detection vary in their specificity and sensitivity, something 
important to consider when using any of them, and to make comparisons. Currently, 
the gold standard test is the PCR for HEV-RNA amplification[185]. In the case of acute 
hepatitis E, a differential diagnosis should be performed to exclude other viral 
hepatitis and other causes (autoimmune, toxic, etc.) of liver disease. HEV-RNA 
detection can be carried out in serum samples (although the viremic period is short) as 
well as in stool samples, in which virions are shed for a longer period of time[4]. HEV 
antigen can also be performed, using double-antibody sandwich enzyme 
immunoassay techniques, which can be detected in serum, feces, or urine[185], 
although it is not extensively used. Acute hepatitis can also be diagnosed by IgM anti-
HEV detection[173]. It is worth mentioning that the time of diagnosis and sample 
extraction is crucial. HEV is not generally taken into account in an initial assessment of 
a sick individual, due to still being regarded as an “emerging” disease, and many 
clinicians have limited knowledge of the disease[4]. This delay in sampling could lead 
to false negative results for viral RNA detection. In these cases, specific IgM testing is 
useful. For chronic infections, diagnosis is performed by detecting the presence of 
HEV-RNA by RT-PCR (and/or its variants Nested-PCR and RT-PCR) in blood for 
more than 6 mo[174]. The titer of antibodies against HEV may be lower in these 
patients, as well as in those immunosuppressed, so detection of HEV IgM and IgG 
should be interpreted with caution[185]. Although viral genotyping is not routinely 
performed, its determination is important in order to understand the clinical and 
epidemiological pattern (especially in risk patients, as immunosuppressed individuals, 
pregnant women, etc.), as well as for viral surveillance and to monitor the introduction 
of new genotypes/strains in a given region.
Antiviral treatment and vaccine
Antiviral therapy is not usually required in acute HEV infection since the virus is 
spontaneously cleared. However, treatment with ribavirin may be considered in cases 
of severe acute hepatitis E or acute-on-chronic liver failure[174].
In the case of chronic infections, ribavirin monotherapy for 3 mo is recommended. 
Decreasing levels of immunosuppression at diagnosis of chronic HEV infection is also 
advisable in solid organ transplant recipients. After 3 mo, HEV-RNA should be 
assessed in stool and serum samples. If RNA is undetectable, European Association for 
the Study of the Liver suggests stopping ribavirin therapy. If RNA replication persists, 
therapy with ribavirin should be continued for an additional 3 mo (6 mo course of 
ribavirin monotherapy in total). In the case of liver transplant recipients with lack of 
response to ribavirin, PEG-IFN therapy for 3 mo could be considered[174,186].
Even though many HEV vaccines have been developed worldwide, only one has 
been licensed in China (Helicon®). This vaccine is based on a recombinant HEV 
peptide derived from genotype 1, corresponding to a fragment of the open reading 
frame 2, which encodes the capsid protein of HEV. It is recommended to be used in 
individuals aged > 16 years and at high risk of HEV infection (food handlers, animal 
husbandry, soldiers, women of childbearing age, travelers to endemic areas, etc.). 
However, very little is known about many aspects of this vaccine, which limits its use, 
such as the efficacy (it has only been proved to prevent symptomatic hepatitis E due to 
genotype 4), immunogenicity and safety, especially in specific populations, like 
pregnant women, transplant patients and subjects with chronic liver disease[187].
The foregoing highlights new challenges regarding hepatitis E worldwide, showing 
that further research about epidemiological, clinical, and virological aspects are 
needed to understand better the different HEV scenarios and implications around the 
world.
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CONCLUSION
In this review, we summarized the most relevant topics that are being analyzed or that 
have recently arisen in the setting of viral hepatitis. Although in recent years 
significant progress has been made in the knowledge of viral hepatitis, there are still 
many aspects to be resolved. It is necessary to continue working on improving 
diagnosis to maintain a constant and continuous epidemiological follow-up of infected 
populations, expand knowledge on the mechanisms of pathogenesis of each virus, 
improve treatment, and develop or improve the efficiency of vaccines. It is important 
to understand that strategies must be both local and global, as this represents that 
most successful path for viral hepatitis to cease being a major public health problem.
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